Literature DB >> 11997295

Pulmonary defences to acute respiratory infection.

Rosemary J Boyton1, Peter J Openshaw.   

Abstract

Of all sites in the body, the lung is perhaps challenged by the greatest onslaught of microbial pathogens, many of which would cause lethal infections if unopposed. The immune response to respiratory infection must, therefore, be rapid and efficient. However, the respiratory tract is a fragile tissue with architecture that is finely designed for gas exchange, so that the price of excessive or inappropriate inflammatory responses may itself be very high. The first line of defence comes from barriers such as mucus and cilia, followed by a battery of mediators that constitute the innate response. These include lactoferrin, lysozyme, collectins and defensins. Activation of these molecules can lead directly to lysis of pathogens, or to destruction through opsonisation or the recruitment of inflammatory cells. The adaptive immune response includes the production of neutralising antibodies and the responses of T lymphocytes. Different populations of T lymphocytes may dramatically alter the balance between clearance of the pathogen and induction of tissue damage depending on the cytokines they secrete.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997295     DOI: 10.1093/bmb/61.1.1

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  24 in total

1.  Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis.

Authors:  María Dolores Juárez-Rodríguez; Jiseon Yang; Rebin Kader; Praveen Alamuri; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  A mutation in the sap operon attenuates survival of nontypeable Haemophilus influenzae in a chinchilla model of otitis media.

Authors:  Kevin M Mason; Robert S Munson; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Human neutrophil peptide in lung chronic allograft dysfunction.

Authors:  Cavan Reilly; Tereza Cervenka; Marshall I Hertz; Trisha Becker; Chris H Wendt
Journal:  Biomarkers       Date:  2011-10-11       Impact factor: 2.658

Review 4.  Hidden risks for pneumonia in Malawi.

Authors:  D G Fullerton; S B Gordon
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

5.  Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies.

Authors:  S de Vallière; G Abate; A Blazevic; R M Heuertz; D F Hoft
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice.

Authors:  Kim S LeMessurier; Yanyan Lin; Jonathan A McCullers; Amali E Samarasinghe
Journal:  Antiviral Res       Date:  2016-08-13       Impact factor: 5.970

7.  Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections.

Authors:  Carmen L Charlton; Esther Babady; Christine C Ginocchio; Todd F Hatchette; Robert C Jerris; Yan Li; Mike Loeffelholz; Yvette S McCarter; Melissa B Miller; Susan Novak-Weekley; Audrey N Schuetz; Yi-Wei Tang; Ray Widen; Steven J Drews
Journal:  Clin Microbiol Rev       Date:  2018-12-12       Impact factor: 26.132

Review 8.  The protective role of antibody responses during Mycobacterium tuberculosis infection.

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 9.  Role of mechanical stress in regulating airway surface hydration and mucus clearance rates.

Authors:  Brian Button; Richard C Boucher
Journal:  Respir Physiol Neurobiol       Date:  2008-06-08       Impact factor: 1.931

10.  Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.

Authors:  Stephen B Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E Zijlstra; Malcolm E Molyneux; John Dennis; Neil French
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.